SynRx Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to SYN818, the company’s proprietary Polθ (DNA polymerase theta) inhibitor, in combination with the PARP inhibitor olaparib, for the treatment of adult patients with BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer who have not received prior PARP inhibitor therapy. The regimen is described as the first Polθ inhibitor combination therapy developed in China to receive FDA Fast Track Designation.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | FDA (United States) |
| Designation Type | Fast Track Designation (FTD) |
| Product | SYN818 (investigational Polθ inhibitor) + olaparib (PARP inhibitor) |
| Indication | BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer; PARP inhibitor–naïve adults |
| Designation Date | 5 October 2026 |
| Distinction | First China-developed Polθ inhibitor combination regimen granted FDA FTD |
| Next Steps | Clinical development and registration timeline – Not disclosed |
Drug Profile & Mechanism of Action
- Molecule: SYN818, an independently developed small-molecule inhibitor of Polθ (DNA polymerase theta), an enzyme central to theta-mediated end joining, a backup DNA double-strand break repair pathway.
- Combination Partner: Olaparib, an established PARP inhibitor that blocks base-excision repair of single-strand DNA damage.
- Scientific Rationale: Simultaneous inhibition of Polθ and PARP delivers a dual blockade of DNA damage repair, exploiting synthetic lethality in BRCA-mutated tumor cells that already harbor deficient homologous recombination repair.
- Resistance Strategy: The combination is specifically designed to address the near-inevitable acquired resistance observed in breast cancer patients following PARP inhibitor monotherapy.
- Clinical Stage & Trial Data: Not disclosed in the announcement.
Disease Landscape – BRCA-Mutated HER2-Negative Breast Cancer
- Elevated Risk: BRCA mutation carriers face a 10- to 20-fold higher risk of developing breast cancer compared with the general population.
- Aggressive Presentation: Affected patients tend to present at a younger age, with higher-stage disease and poorer prognosis, driven by the tumor’s aggressive biology and high recurrence risk.
- Treatment Gap: Although PARP inhibitors have become a cornerstone of therapy, resistance after monotherapy remains almost unavoidable – the precise unmet need the SYN818 + olaparib strategy is engineered to address.
Market Impact & Outlook
- Accelerated Development Pathway: FDA Fast Track Designation is intended to facilitate development and expedite review of therapies for serious conditions with unmet medical need, potentially bringing important new medicines to patients earlier.
- Regulatory Benefits Unlocked: SynRx becomes eligible for more frequent meetings and written communications with the FDA, qualification for Accelerated Approval and Priority Review if relevant criteria are met, and Rolling Review – permitting module-by-module submission of the marketing application rather than a single complete filing.
- Pipeline Positioning: For SYN818 + olaparib, the designation is expected to significantly speed up both clinical development and regulatory submission, strengthening SynRx’s position in the competitive targeted breast cancer landscape.
- Commercial Projections: Revenue forecasts, partnership plans, and trial enrollment timelines – Not disclosed.
Forward-Looking Statements
This brief contains forward-looking statements regarding the clinical development, regulatory review, and commercial potential of SYN818 in combination with olaparib. Fast Track Designation does not guarantee approval. Actual outcomes may differ materially due to risks including clinical trial results, evolving regulatory requirements, competitive dynamics, and the company’s ability to advance its development program.-Fineline Info & Tech
